Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $202.00 target price on the biotechnology company’s stock.

SRPT has been the topic of several other research reports. HC Wainwright reiterated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, December 19th. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Robert W. Baird cut their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Finally, Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $117.06 on Tuesday. The company has a market capitalization of $11.18 billion, a price-to-earnings ratio of 93.65 and a beta of 0.77. The stock’s 50 day moving average is $121.75 and its 200-day moving average is $130.06. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently made changes to their positions in SRPT. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the period. Nkcfo LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. Finally, UMB Bank n.a. increased its position in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after buying an additional 197 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.